Holen Sie sich die Stockscreener-App
9.48
11.53%
0.98
Schlusskurs vom Vortag:
$8.50
Offen:
$8.49
24-Stunden-Volumen:
1.05M
Relative Volume:
0.25
Marktkapitalisierung:
$73.97M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.42M
KGV:
-1.6925
EPS:
-5.6013
Netto-Cashflow:
$-7.45M
1W Leistung:
-33.66%
1M Leistung:
+334.86%
6M Leistung:
-37.34%
1J Leistung:
-59.31%
1-Tages-Spanne:
$8.36
$9.6865
1-Wochen-Bereich:
$7.13
$14.97
52-Wochen-Spanne:
$1.80
$25.92
Cervomed Inc Stock (CRVO) Company Profile
Firmenname
Cervomed Inc
Sektor
Branche
Telefon
(617) 744-4400
Adresse
20 PARK PLAZA, BOSTON
Vergleichen Sie CRVO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
9.48 | 73.97M | 0 | -6.42M | -7.45M | -5.6013 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2024-12-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-12-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-18 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-07-26 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-11-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cervomed Inc Aktie (CRVO) Neueste Nachrichten
FY2025 EPS Estimates for CervoMed Lowered by Chardan Capital - Defense World
CervoMed (CRVO) Projected to Post Quarterly Earnings on Friday - Defense World
CervoMed (NASDAQ:CRVO) Given Buy Rating at D. Boral Capital - Defense World
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
CervoMed Announces Oral Presentation at 19th International - GlobeNewswire
CervoMed Inc. to Present Findings on Neflamapimod in Dementia with Lewy Bodies at AP/PD™ Conference 2025 - Nasdaq
New Clinical Data: CervoMed's Breakthrough Dementia Drug Results Revealed at Global Conference - StockTitan
CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats - Seeking Alpha
CervoMed Stock: Extension Study Data In Dementia Is Potentially Exciting, With Caveats - Seeking Alpha
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Roth Capital Issues Negative Forecast for CervoMed Earnings - Defense World
Q1 Earnings Forecast for CervoMed Issued By Roth Capital - Defense World
Is CervoMed Inc. (CRVO) Among the Best Short Squeeze Stocks to Buy According to Analysts? - Insider Monkey
CervoMed reports FY24 EPS ($2.02), consensus ($1.85) - MSN
CervoMed Inc (CRVO) Reports Q4 Net Loss of $16.3 Million, Grant Revenue at $9.7 Million - GuruFocus.com
Roth Mkm Issues Positive Forecast for CervoMed (NASDAQ:CRVO) Stock Price - Defense World
CervoMed (NASDAQ:CRVO) Given New $21.00 Price Target at Canaccord Genuity Group - Defense World
Best Biotech Stocks To Watch Now – March 17th - Defense World
10 Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey
CervoMed price target raised to $20 from $15 at Roth MKM - TipRanks
Following A Monumental March, Can CRVO Keep The Rally Going In April? - RTTNews
CervoMed sees cash runway into mid-2026 - MSN
CervoMed Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
CervoMed price target raised to $21 from $12 at Canaccord - TipRanks
CervoMed Inc. (CRVO): The Best Short-Term Stock to Buy Right Now - Insider Monkey
Cervomed Inc. Faces Financial Hurdles Due to Regulatory Restrictions on Public Float - TipRanks
Small Cap Stocks To Watch NowMarch 13th - MarketBeat
Peering Into CervoMed's Recent Short Interest - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
CervoMed Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 -March 17, 2025 at 08:19 am EDT - Marketscreener.com
CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
CervoMed's Breakthrough in Lewy Body Dementia Treatment Shows Promise in Latest Financial Report - StockTitan
Why CervoMed Inc. (CRVO) Soared Last Week? - Insider Monkey
These 10 Stocks Posted Double-, Triple-Digit Gains Last Week - Insider Monkey
Small Cap Stocks To Watch TodayMarch 12th - MarketBeat
10 Best Short-Term Stocks to Buy Now with Rebound Potential - Insider Monkey
Capital One, CervoMed, HPE, Eaton, PepsiCo: Trending by Analysts - MSN
CervoMed (CRVO) Stock: 187% Weekly Surge Catches Analysts’ Attention - MoneyCheck
CervoMed (NASDAQ:CRVO) Raised to Buy at Jones Trading - Defense World
Biotech Stocks To Keep An Eye On – March 13th - Defense World
CervoMed (NASDAQ:CRVO) Stock Rating Upgraded by Chardan Capital - Defense World
CervoMed upgraded to Buy at JonesResearch on more confidence in DLB program - Yahoo Finance
‘Turning point in dementia’—CervoMed stock skyrockets on promising dementia drug results - InvestorsObserver
We Think CervoMed (NASDAQ:CRVO) Can Afford To Drive Business Growth - Yahoo Finance
Best Biotech Stocks To Watch Now – March 12th - Defense World
CervoMed (NASDAQ:CRVO) Upgraded at Brookline Capital Management - Defense World
Medical Stocks To Keep An Eye On – March 12th - Defense World
FY2024 EPS Forecast for CervoMed Increased by Analyst - Defense World
CervoMed - The Pharma Letter
CervoMed's Dementia Study's 16-Week Data 'Compelling Enough To Move From Sidelines' Analyst Says - Benzinga India
Jones Trading lifts CervoMed stock rating, sets $15 target - Investing.com India
Finanzdaten der Cervomed Inc-Aktie (CRVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):